A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

PHASE2CompletedINTERVENTIONAL

Enrollment

210

Participants

Timeline

Start Date

March 22, 2017

Primary Completion Date

April 22, 2022

Study Completion Date

May 20, 2022

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

BIOLOGICAL

SHR-1210

SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg

DRUG

Apatinib

Apatinib tablet will be administered orally,once daily until progression

Trial Locations (1)

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03083041 - A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) | Biotech Hunter | Biotech Hunter